Select Publications
Journal articles
2024, 'Meeting report: Women’s Dermatology Society Forum at the 25th World Congress of Dermatology, Singapore, 2023', International Journal of Women's Dermatology, 10, http://dx.doi.org/10.1097/JW9.0000000000000125
,2024, 'The road to publication: Advice from journal editors', Journal of the American Academy of Dermatology, http://dx.doi.org/10.1016/j.jaad.2023.11.038
,2023, 'Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial', Journal of the European Academy of Dermatology and Venereology, 37, pp. e1211 - e1214, http://dx.doi.org/10.1111/jdv.19195
,2023, 'Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study', British Journal of Dermatology, 189, pp. 392 - 399, http://dx.doi.org/10.1093/bjd/ljad182
,2023, 'The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid', Journal of Investigative Dermatology, 143, pp. 1868 - 1871, http://dx.doi.org/10.1016/j.jid.2023.03.1673
,2023, 'Evaluation of skin of color publication trends over the past 2 decades in the Journal of the American Academy of Dermatology', Journal of the American Academy of Dermatology, 89, pp. 614 - 616, http://dx.doi.org/10.1016/j.jaad.2023.05.036
,2023, 'Interventions for bullous pemphigoid', Cochrane Database of Systematic Reviews, 2023, http://dx.doi.org/10.1002/14651858.CD002292.pub4
,2023, 'A Review of the Scoring and Assessment of Keratosis Pilaris', Skin Appendage Disorders, 9, pp. 241 - 251, http://dx.doi.org/10.1159/000529487
,2023, 'Dermatoethics: Nepotism in dermatology residencies', Journal of the American Academy of Dermatology, 89, pp. 193 - 194, http://dx.doi.org/10.1016/j.jaad.2022.01.011
,2023, 'Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE)', Journal of the European Academy of Dermatology and Venereology, 37, pp. 1366 - 1374, http://dx.doi.org/10.1111/jdv.18914
,2023, 'The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial', The Lancet Rheumatology, 5, pp. e413 - e421, http://dx.doi.org/10.1016/S2665-9913(23)00131-5
,2023, 'BG04 Oleogel-S10 (birch triterpenes) in the treatment of epidermolysis bullosa wounds: 24-month efficacy and safety data from the EASE study', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljad113.144
,2023, 'Diacerein 1% Ointment for the Treatment of Epidermolysis Bullosa Simplex: A Randomized, Controlled Trial', Journal of Drugs in Dermatology, 22, pp. 599 - 604, http://dx.doi.org/10.36849/JDD.7108
,2023, 'Phase IIb randomized CONTROL study demonstrates a novel topical isotretinoin formulation, TMB-001, is safe and effective in participants with either recessive X-linked or autosomal recessive lamellar congenital ichthyosis', Clinical and Experimental Dermatology, 48, pp. 623 - 630, http://dx.doi.org/10.1093/ced/llad033
,2023, 'Use of a hybrid teledermatology model in an Australian tertiary hospital during the COVID-19 pandemic', JAAD International, 11, pp. 33 - 34, http://dx.doi.org/10.1016/j.jdin.2022.03.016
,2023, 'A review of JAK and IL-23 inhibitors to treat vitiligo', Australasian Journal of Dermatology, 64, pp. 204 - 212, http://dx.doi.org/10.1111/ajd.14001
,2023, 'Median canaliform nail dystrophy in a 2-year-old boy: Case report and review of the literature', Pediatric Dermatology, 40, pp. 511 - 518, http://dx.doi.org/10.1111/pde.15181
,2023, 'Primary cutaneous amyloidosis: A review of the available studies and gaps in data', Australasian Journal of Dermatology, 64, pp. e121 - e124, http://dx.doi.org/10.1111/ajd.14012
,2023, 'Evaluating the nature and prevalence of glucocorticoid-induced type 2 diabetes mellitus in patients with autoimmune bullous diseases', Clinical and experimental dermatology, 48, pp. 448 - 452, http://dx.doi.org/10.1093/ced/llac137
,2023, 'Fibrillar matrix, Echogenicity, Contour, Thickness, and Suture (FECTS) vs. Global: A comparison of 2 scales developed to assess ultrasound images post rotator cuff repair', Journal of Shoulder and Elbow Surgery, 32, pp. 713 - 728, http://dx.doi.org/10.1016/j.jse.2022.10.035
,2023, 'Gender Equity in Medicine and Dermatology in the United States: The Long Road Traveled and the Journey ahead', Dermatologic Clinics, 41, pp. 265 - 278, http://dx.doi.org/10.1016/j.det.2022.08.007
,2023, 'Clinical manifestations of alopecia in autoimmune blistering diseases: A cross-sectional study', JAAD International, 10, pp. 6 - 13, http://dx.doi.org/10.1016/j.jdin.2022.08.025
,2023, 'The dangers of social media: patients with atopic dermatitis ceasing their basic treatment', Clinical and Experimental Dermatology, 48, pp. 142 - 143, http://dx.doi.org/10.1093/ced/llac056
,2023, 'Eksfolyatif keilit tedavisinde tildrakizumab', Mucosa, 6, pp. 19 - 21, http://dx.doi.org/10.33204/mucosa.1209480
,2023, '307 The study design of a trial of dupilumab in adult patients with bullous pemphigoid (BP): LIBERTY-BP ADEPT', British Journal of Dermatology, 188, http://dx.doi.org/10.1093/bjd/ljac140.007
,2023, 'A life for autoimmune blistering diseases: in memoriam Detlef Zillikens', Frontiers in Immunology, 14, http://dx.doi.org/10.3389/fimmu.2023.1291590
,2023, 'Considerations for the use of immunosuppression for the management of pemphigus during the COVID-19 pandemic with a focus on rituximab: Case reports from a single center experience in Australia', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1149742
,2023, 'Editorial: Challenges of COVID-19 in dermatology patients on immunosuppression: risk, outcome, vaccination and beyond, volume II', Frontiers in Medicine, 10, http://dx.doi.org/10.3389/fmed.2023.1268285
,2023, 'Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study', British Journal of Dermatology, 188, pp. 12 - 21, http://dx.doi.org/10.1093/bjd/ljac001
,2023, 'From the Cochrane Library: Interventions for Pemphigus Vulgaris and Pemphigus Foliaceus', JMIR Dermatology, 6, http://dx.doi.org/10.2196/46812
,2023, 'Practice Dilemma: Expanding Melanonychia in the Paediatric Setting', Skin Appendage Disorders, 9, pp. 58 - 60, http://dx.doi.org/10.1159/000526102
,2023, '390 Examining the risk factors for worsened glucocorticoid morbidity in a prospective, multicentre, international study of patients with autoimmune blistering diseases', Journal of Investigative Dermatology, 143, pp. S67 - S67, http://dx.doi.org/10.1016/j.jid.2023.03.396
,2023, '396 A novel investigator global assessment score for the evaluation of keratosis pilaris', Journal of Investigative Dermatology, 143, pp. S68 - S68, http://dx.doi.org/10.1016/j.jid.2023.03.402
,2023, '459 Demographics, comorbidities and disease severity before dupilumab treatment initiation in Asian patients with atopic dermatitis', Journal of Investigative Dermatology, 143, pp. S79 - S79, http://dx.doi.org/10.1016/j.jid.2023.03.465
,2023, '639 Design of marigold-bp: A phase 2/3 study of nipocalimab in adults with moderate to severe bullous pemphigoid', Journal of Investigative Dermatology, 143, pp. S109 - S109, http://dx.doi.org/10.1016/j.jid.2023.03.646
,2023, 'Dermatology Journal Advisory Boards and Editorial Independence', JAAD International, http://dx.doi.org/10.1016/j.jdin.2023.08.001
,2023, 'Detlef Zillikens, 1958-2022', Journal of Investigative Dermatology, 143, pp. 7 - 8, http://dx.doi.org/10.1016/j.jid.2022.11.001
,2022, 'The efficacy of adding oral sodium cromoglycate to stable treatment for controlling bullous pemphigoid-related pruritus: A retrospective study', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1051804
,2022, 'A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex', Orphanet Journal of Rare Diseases, 17, http://dx.doi.org/10.1186/s13023-022-02433-3
,2022, 'A prospective short-term study to evaluate methodologies for the assessment of disease extent, impact, and wound evolution in patients with dystrophic epidermolysis bullosa', Orphanet Journal of Rare Diseases, 17, http://dx.doi.org/10.1186/s13023-022-02461-z
,2022, 'A translation re-initiation variant in KLHL24 also causes epidermolysis bullosa simplex and dilated cardiomyopathy via intermediate filament degradation', British Journal of Dermatology, 187, pp. 1045 - 1048, http://dx.doi.org/10.1111/bjd.21832
,2022, 'Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients', Dermatologic Therapy, 35, http://dx.doi.org/10.1111/dth.15902
,2022, 'Long-term follow-up of epidermolysis bullosa in real practice shows stability of the Epidermolysis Bullosa Disease Activity and Scarring Index and improvement with some off-label therapies', JAAD International, 9, pp. 105 - 107, http://dx.doi.org/10.1016/j.jdin.2022.07.008
,2022, 'Sebaceous cell carcinoma presenting as ocular Marjolin ulcer following immunosuppression for a chemical burn', Canadian Journal of Ophthalmology, 57, pp. e206 - e208, http://dx.doi.org/10.1016/j.jcjo.2022.02.023
,2022, 'Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic review', JAAD International, 9, pp. 33 - 43, http://dx.doi.org/10.1016/j.jdin.2022.07.005
,2022, 'The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis', Journal of the American Academy of Dermatology, 87, pp. 1455 - 1458, http://dx.doi.org/10.1016/j.jaad.2022.07.028
,2022, 'Bullous pemphigoid—What do we know about the most recent therapies?', Frontiers in Medicine, 9, http://dx.doi.org/10.3389/fmed.2022.1057096
,2022, 'Designing the Future of Dermatology and Venereology', EMJ Dermatology, pp. 18 - 19, http://dx.doi.org/10.33590/emjdermatol/10176803
,2022, 'Investigation of comorbid autoimmune diseases in women with autoimmune bullous diseases: An interplay of autoimmunity and practical implications', International Journal of Women's Dermatology, 8, http://dx.doi.org/10.1097/JW9.0000000000000053
,2022, 'Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris', Journal of the European Academy of Dermatology and Venereology, 36, pp. 852 - 855, http://dx.doi.org/10.1111/jdv.18318
,